Compare AbbVie Inc (ABBV) vs Ambarella Inc (AMBA) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

Ambarella (AMBA) trades at $79.73, up 1.75% with a bullish technical outlook supported by moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and a significant $800M+ long-term edge AI agreement with Hanwha. Revenue grew 16.9% year-over-year in Q1 2027 to $100.4M, though the company remains unprofitable with a -17.18% net income margin. Analyst sentiment is strongly positive with 58% buy ratings and a $108.67 consensus price target representing 36% upside potential.

Ambarella presents a compelling growth story in edge AI with strong analyst support and recent business momentum, but faces execution risks in transitioning to profitability. The stock's current valuation at 8.47x sales appears justified given the company's positioning in the rapidly expanding physical AI market, though investors should monitor progress toward sustainable profitability and competitive pressures in the semiconductor space.